Compare BAFN & DARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BAFN | DARE |
|---|---|---|
| Founded | 1999 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.6M | 21.6M |
| IPO Year | 2021 | 2014 |
| Metric | BAFN | DARE |
|---|---|---|
| Price | $7.20 | $1.77 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 17.8K | ★ 97.9K |
| Earning Date | 04-30-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.10% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $2,807,885.00 |
| Revenue This Year | N/A | $3,195.79 |
| Revenue Next Year | N/A | $95.92 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.80 | $1.27 |
| 52 Week High | $17.16 | $9.19 |
| Indicator | BAFN | DARE |
|---|---|---|
| Relative Strength Index (RSI) | 63.60 | 57.18 |
| Support Level | $6.31 | $1.67 |
| Resistance Level | $8.26 | $1.84 |
| Average True Range (ATR) | 0.48 | 0.13 |
| MACD | 0.12 | 0.02 |
| Stochastic Oscillator | 94.40 | 75.93 |
BayFirst Financial Corp is a bank holding company, it generates its revenue from interest on loans and the gain-on-sale income derived from the sale of loans into the secondary market. The company serves a broad spectrum of individuals, families, and small businesses, supported by national business lines in residential and SBA lending and technology platforms. The primary source of funding for its loans is deposits. BayFirst measures performance through net interest income after provision for loan losses, return on average assets, and return on average common equity, while maintaining appropriate regulatory leverage and risk-based capital ratios. The company has various segment such as Real Estate(Residential, Commercial, and Construction & Land), Commercial and Industrial, Consumer.
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.